Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold

YAMAÇ, AYLİN HATİCE; BASHİROV, Nemat; NASIFOV, Meherrem; TAŞTAN, Ahmet; GÖKTEKİN, Ömer; YILDIZ, Abdulkadir

Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold

Aylin Hatice YAMAÇ, (Bezmialem Foundation University,)

Abdulkadir YILDIZ, (Bezmialem Foundation University,)

Meherrem NASIFOV, (Bezmialem Foundation University,)

Ahmet TAŞTAN, (Bezmialem Foundation University,)

Nemat BASHİROV, (Department of Cardiology, Şifa University Hospital, İzmir, Turkey)

Ömer GÖKTEKİN (Bezmialem Foundation University,)

Türk Kardiyoloji Derneği Arşivi

0 0

Yıl: 2016 Cilt: 44 Sayı: 8 Sayfa Aralığı: 647 - 655 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold

Öz:

Amaç: Kronik tam tıkanma (KTT) lezyonlarının everolimus salgılayan eriyen stentler (bioresorbable vascular scaffold BVS) ile tedavi edilmesi kısa dönem takipte güvenilir ve etkilidir. Bu çalışma KTT lezyonlarının BVS ile tedavisinin bir yıllık klinik ve anjiyografik sonuçlarını araştırmayı hedeflemektedir.Yöntemler: Bu çalışmaya 35 KKT lezyonu başarıyla tedavi edilen 30 hasta alındı. Kantitatif koroner anjiyografi (KKA) ortalama 402 günlük takip süresi sonucunda yapıldı. Primer sonlanım noktaları tüm nedenlere bağlı ölüm, kardiyak ölüm, hedef damara bağlı ölümcül olmayan miyokart enfarktüsü, hedef damar revaskülarizasyonu (HDR), semptom oluşturan hedef lezyon revaskülarizasyonu (HLR) ve BVS trombozu olarak belirlendi.Bulgular: Kantitatif koroner anjiyografi analizinde minimal lümen çapı 2.14±0.50 mm, geç lümen kaybı 0.38±0.54 mm olarak ölçüldü. Ortanca 542 günlük takip süresince bir kardiyak ölüm, beş HDR ve üç HLR saptandı. BVS trombozu gelişmedi.Sonuç: KTT tedavisinde Absorb BVS kullanımı orta dönem takipte güvenilir ve etkilidir. Geç lümen kaybı ilaç salınımlı stentler ile benzer bulunmuştur.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Kronik tam tıkanma lezyonlarının everolimus salgılayan "bioresorbable vascular scaffold" ile tedavisinin bir yıllık takipte klinik ve anjiyografik sonuçları

Öz:

Objective: Treatment of chronic total occlusion (CTO) with everolimus-eluting bioresorbable vascular scaffold (BVS) is safe and effective at short-term follow-up (FU). The current study investigated clinical and angiographic outcomes after treatment of CTO with BVS at >1 year.Methods: Thirty patients who underwent successful recanalization of 35 CTOs were included in this study. Quantitative coronary angiography (QCA) was performed at median FU period of 402 days. Clinical endpoints analyzed included all-cause mortality, cardiac death, non-fatal target vessel myocardial infarction, target vessel revascularization (TVR), symptom-driven target lesion revascularization (TLR), and BVS thrombosis. Results: QCA analysis revealed in-scaffold minimal luminal diameter of 2.14±0.50 mm and late lumen loss (LLL) of 0.38±0.54 mm. One cardiac death, 5 cases with TVR, and 3 cases with TLR were detected at median FU time of 542 days. No BVS thrombosis was observed.Conclusion: The Absorb BVS was safe and effective in the treatment of CTO with acceptable LLL at mid-term FU, comparable to drug eluting stents.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Latib A, Costopoulos C, Naganuma T, Colombo A. Which patients could benefit the most from bioresorbable vascular scaffold implant: from clinical trials to clinical practice. Minerva Cardioangiol 2013;61:255-62.
2. Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia-Garcia HM, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv 2013;6:999-1009.
3. Goktekin O, Yamac AH, Latib A, Tastan A, Panoulas VF, Sato K, et al. Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients With Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results. J Invasive Cardiol 2015;27:461-6.
4. Judkins MP. Selective coronary arteriography. I. A percutaneous transfemoral technic. Radiology 1967;89:815-24.
5. Gronenschild E, Janssen J, Tijdens F. CAAS. II: A second generation system for off-line and on-line quantitative coronary angiography. Cathet Cardiovasc Diagn 1994;33:61-75.
6. Pawlowski T, Prati F, Kulawik T, Ficarra E, Bil J, Gil R. Optical coherence tomography criteria for defining functional severity of intermediate lesions: a comparative study with FFR. Int J Cardiovasc Imaging 2013;29:1685-91.
7. Vaquerizo B, Barros A, Pujadas S, Bajo E, Estrada D, Miranda-Guardiola F, et al. Bioresorbable everolimus-eluting vascular scaffold for the treatment of chronic total occlusions: CTO-ABSORB pilot study. EuroIntervention 2015;11:555- 63.
8. Karanasos A, Simsek C, Gnanadesigan M, van Ditzhuijzen NS, Freire R, Dijkstra J, et al. OCT assessment of the longterm vascular healing response 5 years after everolimuseluting bioresorbable vascular scaffold. J Am Coll Cardiol 2014;64:2343-56.
9. Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, et al. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 2013;99:98-105.
10. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014;9:1271-84.
11. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015;10:1144-53.
12. Colmenarez HJ, Escaned J, Fernández C, Lobo L, Cano S, del Angel JG, et al. Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1854- 66.
13. Tian NL, Gami SK, Ye F, Zhang JJ, Liu ZZ, Lin S, et al. Angiographic and clinical comparisons of intravascular ultrasound- versus angiography-guided drug-eluting stent implantation for patients with chronic total occlusion lesions: two-year results from a randomised AIR-CTO study. EuroIntervention 2015;10:1409-17.

APA	YAMAÇ A, YILDIZ A, NASIFOV M, TAŞTAN A, BASHİROV N, GÖKTEKİN Ö (2016). Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold. , 647 - 655.
Chicago	YAMAÇ AYLİN HATİCE,YILDIZ Abdulkadir,NASIFOV Meherrem,TAŞTAN Ahmet,BASHİROV Nemat,GÖKTEKİN Ömer Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold. (2016): 647 - 655.
MLA	YAMAÇ AYLİN HATİCE,YILDIZ Abdulkadir,NASIFOV Meherrem,TAŞTAN Ahmet,BASHİROV Nemat,GÖKTEKİN Ömer Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold. , 2016, ss.647 - 655.
AMA	YAMAÇ A,YILDIZ A,NASIFOV M,TAŞTAN A,BASHİROV N,GÖKTEKİN Ö Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold. . 2016; 647 - 655.
Vancouver	YAMAÇ A,YILDIZ A,NASIFOV M,TAŞTAN A,BASHİROV N,GÖKTEKİN Ö Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold. . 2016; 647 - 655.
IEEE	YAMAÇ A,YILDIZ A,NASIFOV M,TAŞTAN A,BASHİROV N,GÖKTEKİN Ö "Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold." , ss.647 - 655, 2016.
ISNAD	YAMAÇ, AYLİN HATİCE vd. "Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold". (2016), 647-655.

APA	YAMAÇ A, YILDIZ A, NASIFOV M, TAŞTAN A, BASHİROV N, GÖKTEKİN Ö (2016). Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold. Türk Kardiyoloji Derneği Arşivi, 44(8), 647 - 655.
Chicago	YAMAÇ AYLİN HATİCE,YILDIZ Abdulkadir,NASIFOV Meherrem,TAŞTAN Ahmet,BASHİROV Nemat,GÖKTEKİN Ömer Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold. Türk Kardiyoloji Derneği Arşivi 44, no.8 (2016): 647 - 655.
MLA	YAMAÇ AYLİN HATİCE,YILDIZ Abdulkadir,NASIFOV Meherrem,TAŞTAN Ahmet,BASHİROV Nemat,GÖKTEKİN Ömer Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold. Türk Kardiyoloji Derneği Arşivi, vol.44, no.8, 2016, ss.647 - 655.
AMA	YAMAÇ A,YILDIZ A,NASIFOV M,TAŞTAN A,BASHİROV N,GÖKTEKİN Ö Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold. Türk Kardiyoloji Derneği Arşivi. 2016; 44(8): 647 - 655.
Vancouver	YAMAÇ A,YILDIZ A,NASIFOV M,TAŞTAN A,BASHİROV N,GÖKTEKİN Ö Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold. Türk Kardiyoloji Derneği Arşivi. 2016; 44(8): 647 - 655.
IEEE	YAMAÇ A,YILDIZ A,NASIFOV M,TAŞTAN A,BASHİROV N,GÖKTEKİN Ö "Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold." Türk Kardiyoloji Derneği Arşivi, 44, ss.647 - 655, 2016.
ISNAD	YAMAÇ, AYLİN HATİCE vd. "Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold". Türk Kardiyoloji Derneği Arşivi 44/8 (2016), 647-655.